Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   Meta Analysis       

Factors affecting different COVID-19 outcomes in patients with systemic lupus erythematosus during the second pandemic wave of COVID-19 in China

Feb 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Severe case 39% Improvement Relative Risk HCQ for COVID-19  Liu et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 301 patients in China (December 2022 - February 2023) Lower severe cases with HCQ (not stat. sig., p=0.26) c19hcq.org Liu et al., Lupus, February 2024 FavorsHCQ Favorscontrol 0 0.5 1 1.5 2+
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020, now with p < 0.00000000001 from 421 studies, recognized in 56 countries.
No treatment is 100% effective. Protocols combine treatments.
5,400+ studies for 117 treatments. c19hcq.org
Retrospective 301 consecutive SLE patients with COVID-19, showing lower risk of severe outcomes with HCQ use, with statistical significance in multivariable adjusted model 1 but not model 2.
Standard of Care (SOC) for COVID-19 in the study country, China, is average with moderate efficacy for approved treatments1.
risk of severe case, 39.0% lower, OR 0.61, p = 0.26, treatment 55, control 246, adjusted per study, multivariable, model 2, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Liu et al., 5 Feb 2024, retrospective, China, peer-reviewed, 6 authors, study period December 2022 - February 2023.
This PaperHCQAll
DOI record: { "DOI": "10.1177/09612033241230736", "ISSN": [ "0961-2033", "1477-0962" ], "URL": "http://dx.doi.org/10.1177/09612033241230736", "abstract": "<jats:sec><jats:title>Objective</jats:title><jats:p> To investigate characteristics associated with different COVID-19 outcomes of people with systemic lupus erythematosus (SLE) and COVID-19 during the second pandemic wave of COVID-19 in China. </jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p> In this retrospective study, people with SLE and COVID-19 who visited the First Affiliated Hospital of Nanchang University from December 2022 and February 2023 were subjected to this study. The three possible outcomes were listed in order of ordinal severity: (1) not hospitalized, (2) hospitalized but not receiving oxygenation, and (3) hospitalized with any ventilation or oxygenation. A multivariable ordinal logistic regression model was built to examine the association between COVID-19 severity and demographic traits, medications, comorbidities, and disease activity. Furthermore, among the 301 SLE patients included in our study, only two patients experienced mortality. In order to maintain statistical rigor, we have included these two deceased patients in the outcome measure of hospitalized with any ventilation or oxygenation. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> A total of 301 patients with SLE were enrolled in this study. The multivariate ordinal logistic regression analyses indicated that high SLE disease activity (vs remission; OR 39.04, 95% CI 3.08 to 494.44, p = .005) was associated with more severe outcomes. Three doses of COVID-19 vaccination (OR 0.19, 95% CI 0.07 to 0.51, p = .001), glucocorticoids dose (1–5 mg/day 0.14, 0.03 to 0.73, p = .020, and 6–9 mg/day 0.12, 0.02 to 0.61, p = .010), and more intensive immunosuppression drugs (0.34, 0.12 to 0.97, p = .044) were associated with better outcomes. In age-adjusted and sex-adjusted models, telitacicept (6.66, 1.35 to 32.86, p = .020) and rituximab (7.81, 1.87 to 32.66, p = .005) were associated with more severe outcomes. Hydroxychloroquine (0.47, 0.25 to 0.88, p = .018) was associated with favorable outcomes. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> Different COVID-19 outcomes in people with SLE are mostly driven by COVID-19 vaccination, medications, and activity SLE. More importantly, three doses of COVID-19 vaccination may be associated with better outcomes. </jats:p></jats:sec>", "alternative-id": [ "10.1177/09612033241230736" ], "author": [ { "ORCID": "http://orcid.org/0000-0002-9144-1623", "affiliation": [ { "name": "Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China" } ], "authenticated-orcid": false, "family": "Liu", "given": "Peng-Cheng", "sequence": "first" }, { "affiliation": [ { "name": "Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China" } ], "family": "Zhang", "given": "Min", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0001-9629-8558", "affiliation": [ { "name": "Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China" } ], "authenticated-orcid": false, "family": "Li", "given": "Jian-Bin", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China" } ], "family": "Peng", "given": "Yi-Lin", "sequence": "additional" }, { "affiliation": [ { "name": "Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China" } ], "family": "Yu", "given": "Shu-Jiao", "sequence": "additional" }, { "ORCID": "http://orcid.org/0000-0003-0110-4912", "affiliation": [ { "name": "Department of Rheumatology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China" } ], "authenticated-orcid": false, "family": "Wu", "given": "Rui", "sequence": "additional" } ], "container-title": "Lupus", "container-title-short": "Lupus", "content-domain": { "crossmark-restriction": true, "domain": [ "journals.sagepub.com" ] }, "created": { "date-parts": [ [ 2024, 2, 5 ] ], "date-time": "2024-02-05T11:44:34Z", "timestamp": 1707133474000 }, "deposited": { "date-parts": [ [ 2024, 2, 5 ] ], "date-time": "2024-02-05T11:44:40Z", "timestamp": 1707133480000 }, "funder": [ { "DOI": "10.13039/501100001809", "award": [ "NO.82260898" ], "doi-asserted-by": "publisher", "name": "National Natural Science Foundation of China" } ], "indexed": { "date-parts": [ [ 2024, 2, 6 ] ], "date-time": "2024-02-06T00:35:24Z", "timestamp": 1707179724867 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 2, 5 ] ] }, "language": "en", "license": [ { "URL": "https://journals.sagepub.com/page/policies/text-and-data-mining-license", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 2, 5 ] ], "date-time": "2024-02-05T00:00:00Z", "timestamp": 1707091200000 } } ], "link": [ { "URL": "http://journals.sagepub.com/doi/pdf/10.1177/09612033241230736", "content-type": "application/pdf", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://journals.sagepub.com/doi/full-xml/10.1177/09612033241230736", "content-type": "application/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "http://journals.sagepub.com/doi/pdf/10.1177/09612033241230736", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "179", "original-title": [], "prefix": "10.1177", "published": { "date-parts": [ [ 2024, 2, 5 ] ] }, "published-online": { "date-parts": [ [ 2024, 2, 5 ] ] }, "publisher": "SAGE Publications", "reference": [ { "DOI": "10.1038/s41586-020-2521-4", "doi-asserted-by": "publisher", "key": "bibr1-09612033241230736" }, { "DOI": "10.1016/S2665-9913(20)30227-7", "doi-asserted-by": "publisher", "key": "bibr2-09612033241230736" }, { "DOI": "10.1016/S2665-9913(21)00151-X", "doi-asserted-by": "publisher", "key": "bibr3-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2020-217763", "doi-asserted-by": "publisher", "key": "bibr4-09612033241230736" }, { "DOI": "10.1080/1744666X.2021.1847084", "doi-asserted-by": "publisher", "key": "bibr5-09612033241230736" }, { "DOI": "10.1001/jama.2020.12839", "doi-asserted-by": "publisher", "key": "bibr6-09612033241230736" }, { "DOI": "10.1038/s41586-020-2918-0", "doi-asserted-by": "publisher", "key": "bibr7-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2021-221636", "doi-asserted-by": "publisher", "key": "bibr8-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2018-214819", "doi-asserted-by": "publisher", "key": "bibr9-09612033241230736" }, { "DOI": "10.1002/art.1780350606", "doi-asserted-by": "publisher", "key": "bibr10-09612033241230736" }, { "DOI": "10.1038/s41586-020-2798-3", "doi-asserted-by": "publisher", "key": "bibr11-09612033241230736" }, { "DOI": "10.1038/s41591-021-01377-8", "doi-asserted-by": "publisher", "key": "bibr12-09612033241230736" }, { "DOI": "10.1056/NEJMoa2028436", "doi-asserted-by": "publisher", "key": "bibr13-09612033241230736" }, { "DOI": "10.1056/NEJMoa2022483", "doi-asserted-by": "publisher", "key": "bibr14-09612033241230736" }, { "DOI": "10.1056/NEJMoa2034201", "doi-asserted-by": "publisher", "key": "bibr15-09612033241230736" }, { "DOI": "10.1056/NEJMoa2027906", "doi-asserted-by": "publisher", "key": "bibr16-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2021-220272", "doi-asserted-by": "publisher", "key": "bibr17-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2021-220736", "doi-asserted-by": "publisher", "key": "bibr18-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2021-220647", "doi-asserted-by": "publisher", "key": "bibr19-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2021-220597", "doi-asserted-by": "publisher", "key": "bibr20-09612033241230736" }, { "author": "Graña C", "first-page": "Cd015477", "journal-title": "Cochrane Database Syst Rev", "key": "bibr21-09612033241230736", "volume": "12", "year": "2022" }, { "DOI": "10.1016/S1473-3099(22)00345-0", "doi-asserted-by": "publisher", "key": "bibr22-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2020-218244", "doi-asserted-by": "publisher", "key": "bibr23-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2020-219498", "doi-asserted-by": "publisher", "key": "bibr24-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2021-220134", "doi-asserted-by": "publisher", "key": "bibr25-09612033241230736" }, { "DOI": "10.1177/0961203319860579", "doi-asserted-by": "publisher", "key": "bibr26-09612033241230736" }, { "DOI": "10.1002/cpdd.1136", "doi-asserted-by": "publisher", "key": "bibr27-09612033241230736" }, { "DOI": "10.1136/annrheumdis-2021-220503", "doi-asserted-by": "publisher", "key": "bibr28-09612033241230736" }, { "DOI": "10.1016/j.lansea.2023.100154", "doi-asserted-by": "publisher", "key": "bibr29-09612033241230736" } ], "reference-count": 29, "references-count": 29, "relation": {}, "resource": { "primary": { "URL": "http://journals.sagepub.com/doi/10.1177/09612033241230736" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Rheumatology" ], "subtitle": [], "title": "Factors affecting different COVID-19 outcomes in patients with systemic lupus erythematosus during the second pandemic wave of COVID-19 in China", "type": "journal-article", "update-policy": "http://dx.doi.org/10.1177/sage-journals-update-policy" }
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit